JP2013505930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505930A5 JP2013505930A5 JP2012530402A JP2012530402A JP2013505930A5 JP 2013505930 A5 JP2013505930 A5 JP 2013505930A5 JP 2012530402 A JP2012530402 A JP 2012530402A JP 2012530402 A JP2012530402 A JP 2012530402A JP 2013505930 A5 JP2013505930 A5 JP 2013505930A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkenyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- -1 substituted Chemical class 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- DISVMXDWAMMVLT-UHFFFAOYSA-N 10-benzyl-2-(2-chlorophenyl)-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCCN3C(=O)C=C2N1 DISVMXDWAMMVLT-UHFFFAOYSA-N 0.000 claims 1
- GDWVEYKRLIYGKX-UHFFFAOYSA-N 10-benzyl-2-(2-methoxyphenyl)-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCCN3C(=O)C=C2N1 GDWVEYKRLIYGKX-UHFFFAOYSA-N 0.000 claims 1
- XCEHGPJYDIOHTC-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-(pyridin-2-ylmethyl)-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4N=CC=CC=4)CCCN3C(=O)C=C2N1 XCEHGPJYDIOHTC-UHFFFAOYSA-N 0.000 claims 1
- PQSVOKDNSZFBAD-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(1-methylpyrazol-3-yl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound CN1C=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=N1 PQSVOKDNSZFBAD-UHFFFAOYSA-N 0.000 claims 1
- IDCYRHQZIMSXNT-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(2-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 IDCYRHQZIMSXNT-UHFFFAOYSA-N 0.000 claims 1
- YTGBUSQTIGZPPO-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(2-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 YTGBUSQTIGZPPO-UHFFFAOYSA-N 0.000 claims 1
- JENINVSFDRKCKM-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(3-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=C1 JENINVSFDRKCKM-UHFFFAOYSA-N 0.000 claims 1
- FWOUVVOPMDNLTL-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(3-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=C1 FWOUVVOPMDNLTL-UHFFFAOYSA-N 0.000 claims 1
- WMIICUNBBWCKDS-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(4-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound C1=CC(Cl)=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 WMIICUNBBWCKDS-UHFFFAOYSA-N 0.000 claims 1
- FCZWOXRJSYVTON-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(4-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound C1=CC(OC)=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 FCZWOXRJSYVTON-UHFFFAOYSA-N 0.000 claims 1
- FQIOOGDMVOLMFS-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,7,8,10-tetrahydropyrazolo[4,5]pyrido[5,6-a][1,4]oxazine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3COCCN3C(=O)C=C2N1 FQIOOGDMVOLMFS-UHFFFAOYSA-N 0.000 claims 1
- GNVGXVJPFSNSKT-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,7,8,9,10,11-hexahydropyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CNCCCN3C(=O)C=C2N1 GNVGXVJPFSNSKT-UHFFFAOYSA-N 0.000 claims 1
- JRKSQSWCFISGJK-UHFFFAOYSA-N 2-(2-methoxyphenyl)-10-(pyridin-2-ylmethyl)-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4N=CC=CC=4)CCCN3C(=O)C=C2N1 JRKSQSWCFISGJK-UHFFFAOYSA-N 0.000 claims 1
- DQKCDKBMEPYLJK-UHFFFAOYSA-N 2-(2-methoxyphenyl)-10-[(3-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)OC)N4)=O)=O)CCC2)=C1 DQKCDKBMEPYLJK-UHFFFAOYSA-N 0.000 claims 1
- COIMBYVEHYQEMU-UHFFFAOYSA-N 9-benzyl-2-(2-chlorophenyl)-3,7,8,10-tetrahydropyrazolo[4,5]pyrido[5,6-a]pyrazine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCN3C(=O)C=C2N1 COIMBYVEHYQEMU-UHFFFAOYSA-N 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000003455 Anaphylaxis Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- AQVJNNMDCSWPMV-UHFFFAOYSA-N C1(C=2N(C(C=CN1)=O)CC=CC=2)=O Chemical compound C1(C=2N(C(C=CN1)=O)CC=CC=2)=O AQVJNNMDCSWPMV-UHFFFAOYSA-N 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 210000003027 Ear, Inner Anatomy 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 108020005203 Oxidases Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 230000001079 digestive Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- MDUOHPOFQAAQIX-UHFFFAOYSA-N methyl 2-[4-(1-benzyl-2,5,6,7-tetrahydro-1,4-diazepin-3-yl)-2-(2-chlorophenyl)-3-oxo-1H-pyrazol-5-yl]acetate Chemical compound O=C1C(C=2CN(CC=3C=CC=CC=3)CCCN=2)=C(CC(=O)OC)NN1C1=CC=CC=C1Cl MDUOHPOFQAAQIX-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 claims 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- QAGPTTNFAWOFFR-UHFFFAOYSA-N tert-butyl 2-(2-chlorophenyl)-1,5-dioxo-7,8,9,11-tetrahydro-3H-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-10-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCN(C(C=2)=O)C1=C(C1=O)C=2NN1C1=CC=CC=C1Cl QAGPTTNFAWOFFR-UHFFFAOYSA-N 0.000 claims 1
- 0 C*C(*)(C(*)(*)C(C)(C)C(*)(*)*(C)*C1(C)*)N/I1=C(\C(C(C)C(OC)=O)NN1*)/C1=O Chemical compound C*C(*)(C(*)(*)C(C)(C)C(*)(*)*(C)*C1(C)*)N/I1=C(\C(C(C)C(OC)=O)NN1*)/C1=O 0.000 description 8
Claims (17)
- 式(I):
- 請求項1による誘導体であって、R1が、必要に応じて置換されるアリール及び必要に応じて置換されるヘテロアリールから選ばれ;R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R17、R18、X及びnが、該先行請求項において定義される通りである、誘導体。
- 請求項1又は2による誘導体であって、X がNR12であり;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R17、R18、及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1から3のいずれか1項による誘導体であって、XがNHであり;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1又は2による誘導体であって、XがOであり;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R13、R14、及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1から3のいずれか1項による誘導体であって、R12が、必要に応じて置換されるアリールC1−C6、及び必要に応じて置換されるヘテロアリールC1−C6アルキルから選ばれ;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R13、R14、X及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1から3のいずれか1項による誘導体であって、R12が、必要に応じて置換されるアルコキシカルボニルであり;R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R13、R14、X及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1から7のいずれか1項による誘導体であって、R2、R3、R4、R5、R6、R7、R8、R9、R10及びR11がHであり;R1、R12、R13、R14、R17、R18、X 及びnが、該先行請求項のいずれか1項に定義される通りである、誘導体。
- 請求項1から8のいずれか1項による誘導体であって、下記の群:
2−(2−クロロフェニル)−10−(ピリジン−2−イルメチル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ [4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
10−ベンジル−2−(2−メトキシフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
10−ベンジル−2−(2−クロロフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4]ピリド[1,2−a] [1,4]ジアゼピン−1,5(7H)−ジオン;
10−(2−クロロベンジル)−2−(2−クロロフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−10−(3−メトキシベンジル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
10−(3−クロロベンジル)−2−(2−クロロフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4]ピリド[1,2−a][1,4] ジアゼピン−1,5(7H)−ジオン;
tert−ブチル 2−(2−クロロフェニル)−1,5−ジオキソ−2,3,5,8,9,11−ヘキサヒドロ−1H−ピラゾロ [4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−10(7H)−カルボキシレート;
10−(4−クロロベンジル)−2−(2−クロロフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a] [1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−10−(2−メトキシベンジル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−10−(4−メトキシベンジル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−10−(フラン−3−イルメチル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4] ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
9−ベンジル−2−(2−クロロフェニル)−2,3,7,8,9,10−ヘキサヒドロピラゾロ[4',3':3,4]ピリド[1,2−a] ピラジン−1,5−ジオン;
2−(2−クロロフェニル)−2,3,7,8−テトラヒドロ−1H−ピラゾロ[4',3':3,4]ピリド[2,1−c][1,4]オキサジン−1,5 (10H)−ジオン;
2−(2−メトキシフェニル)−10−(ピリジン−2−イルメチル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ [4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
10−(3−メトキシベンジル)−2−(2−メトキシフェニル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ [4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;
2−(2−クロロフェニル)−10−[(1−メチル−1H−ピラゾル−3−イル)メチル]−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ[4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン;及び
2−(2−クロロフェニル)−10−(ピリジン−3−イルメチル)−2,3,8,9,10,11−ヘキサヒドロ−1H−ピラゾロ [4',3':3,4]ピリド[1,2−a][1,4]ジアゼピン−1,5(7H)−ジオン
から選ばれる、誘導体。 - 請求項1から9のいずれか1項による少なくとも一つの誘導体、及び、その、薬学的に許容可能な担体、希釈剤、又は賦形剤を含む製剤組成物。
- 薬剤として使用するための、請求項1から9のいずれか1項による誘導体。
- 請求項1から9のいずれか1項によるピラゾリンジオン誘導体であって、循環器障害、呼吸器障害、代謝障害、皮膚障害、骨障害、神経炎症及び/又は神経変性障害、腎臓病、生殖器障害、眼球及び/又は水晶体を冒す疾患及び/又は内耳を冒す病態、炎症性障害、肝臓疾患、痛み、癌、アレルギー障害、外傷、敗血症、出血性及びアナフィラキシーショック、消化器系の障害、血管形成、血管形成依存性病態、及び他の、ニコチンアミドアデニンジヌクレオチドリン酸(NADPH)オキシダーゼ関連性疾患及び/又は障害から選ばれる疾患又は病態を治療するための、誘導体。
- 請求項13による中間産物であって:
メチル[(4Z)−4−(4−ベンジル−1,4−ジアゼパン−2−イリデン)−1−(2−クロロフェニル)−5−オキソ−4,5−ジヒドロ−1H−ピラゾル3−イル]アセテート;及びメチル[(4Z)−4−(4−ベンジル−1,4−ジアゼパン−2−イリデン)−1−(2−メトキシフェニル)−5−オキソ−4,5−ジヒドロ−1H−ピラゾル3−イル]アセテートから成る群から選ばれる中間産物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09171466A EP2305679A1 (en) | 2009-09-28 | 2009-09-28 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
EP09171466.7 | 2009-09-28 | ||
PCT/IB2010/054329 WO2011036651A1 (en) | 2009-09-28 | 2010-09-27 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013505930A JP2013505930A (ja) | 2013-02-21 |
JP2013505930A5 true JP2013505930A5 (ja) | 2013-08-08 |
JP5707406B2 JP5707406B2 (ja) | 2015-04-30 |
Family
ID=41347804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012530402A Expired - Fee Related JP5707406B2 (ja) | 2009-09-28 | 2010-09-27 | Nadphオキシダーゼインヒビターとしてのピラゾリンジオン誘導体 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9394306B2 (ja) |
EP (2) | EP2305679A1 (ja) |
JP (1) | JP5707406B2 (ja) |
KR (1) | KR101791273B1 (ja) |
CN (1) | CN102686590B (ja) |
AU (1) | AU2010299487B2 (ja) |
BR (1) | BR112012004208A2 (ja) |
CA (1) | CA2770278C (ja) |
CY (1) | CY1119780T1 (ja) |
DK (1) | DK2483271T3 (ja) |
ES (1) | ES2644857T3 (ja) |
HK (1) | HK1171748A1 (ja) |
HR (1) | HRP20171638T1 (ja) |
HU (1) | HUE035058T2 (ja) |
IL (1) | IL218814A0 (ja) |
LT (1) | LT2483271T (ja) |
ME (1) | ME03040B (ja) |
NO (1) | NO2483271T3 (ja) |
PL (1) | PL2483271T3 (ja) |
PT (1) | PT2483271T (ja) |
RS (1) | RS56542B1 (ja) |
RU (1) | RU2569855C2 (ja) |
SI (1) | SI2483271T1 (ja) |
WO (1) | WO2011036651A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
WO2013078261A1 (en) * | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
CA2867412A1 (en) * | 2012-03-16 | 2013-09-19 | Mona Wilcke | Thiophene- based compounds exhibiting nox4 inhibitory activity and use thereof in therapy |
WO2014064118A1 (en) | 2012-10-24 | 2014-05-01 | Glucox Biotech Ab | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase |
EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
WO2016133446A1 (en) | 2015-02-16 | 2016-08-25 | Glucox Biotech Ab | N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine |
EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
IL273741B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
JP2022519323A (ja) | 2019-02-06 | 2022-03-22 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931407A (en) | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
DE19518082A1 (de) | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
WO1998037068A1 (en) | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
WO2002088122A1 (fr) | 2001-04-26 | 2002-11-07 | Ajinomoto Co., Inc. | Composes heterocycliques |
CN100343255C (zh) | 2002-04-23 | 2007-10-17 | 盐野义制药株式会社 | 吡唑并[1,5-a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂 |
AU2003267980A1 (en) | 2002-07-03 | 2004-01-23 | Janssen Pharmaceutica, N.V. | Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders |
NZ542059A (en) | 2003-02-28 | 2009-11-27 | Florey Howard Inst | Therapeutic compositions comprising an aryl sulphonate such as suramin, for the treatment of a pathological condition or event of the systemic vasculature resulting form the producation of reactive oxygen species. |
JPWO2004089412A1 (ja) | 2003-04-08 | 2006-07-06 | 三菱ウェルファーマ株式会社 | 特異的nad(p)hオキシダーゼ抑制剤 |
TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
AU2005294404A1 (en) | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for Alzheimer's disease |
FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
US20070014739A1 (en) | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス, インコーポレイテッド | 疾患および障害のための化合物 |
EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
AR069526A1 (es) | 2007-12-03 | 2010-01-27 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
-
2009
- 2009-09-28 EP EP09171466A patent/EP2305679A1/en not_active Withdrawn
-
2010
- 2010-09-27 WO PCT/IB2010/054329 patent/WO2011036651A1/en active Application Filing
- 2010-09-27 BR BR112012004208A patent/BR112012004208A2/pt not_active Application Discontinuation
- 2010-09-27 US US13/394,904 patent/US9394306B2/en not_active Expired - Fee Related
- 2010-09-27 RS RS20171071A patent/RS56542B1/sr unknown
- 2010-09-27 AU AU2010299487A patent/AU2010299487B2/en not_active Ceased
- 2010-09-27 CN CN201080041718.5A patent/CN102686590B/zh not_active Expired - Fee Related
- 2010-09-27 NO NO10782688A patent/NO2483271T3/no unknown
- 2010-09-27 KR KR1020127007664A patent/KR101791273B1/ko active IP Right Grant
- 2010-09-27 PL PL10782688T patent/PL2483271T3/pl unknown
- 2010-09-27 CA CA2770278A patent/CA2770278C/en not_active Expired - Fee Related
- 2010-09-27 RU RU2012117796/04A patent/RU2569855C2/ru not_active IP Right Cessation
- 2010-09-27 HU HUE10782688A patent/HUE035058T2/en unknown
- 2010-09-27 ME MEP-2017-258A patent/ME03040B/me unknown
- 2010-09-27 SI SI201031580T patent/SI2483271T1/en unknown
- 2010-09-27 ES ES10782688.5T patent/ES2644857T3/es active Active
- 2010-09-27 LT LTEP10782688.5T patent/LT2483271T/lt unknown
- 2010-09-27 PT PT107826885T patent/PT2483271T/pt unknown
- 2010-09-27 DK DK10782688.5T patent/DK2483271T3/da active
- 2010-09-27 EP EP10782688.5A patent/EP2483271B1/en active Active
- 2010-09-27 JP JP2012530402A patent/JP5707406B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-25 IL IL218814A patent/IL218814A0/en unknown
- 2012-12-05 HK HK12112534.4A patent/HK1171748A1/zh not_active IP Right Cessation
-
2017
- 2017-10-26 HR HRP20171638TT patent/HRP20171638T1/hr unknown
- 2017-11-03 CY CY20171101161T patent/CY1119780T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013505930A5 (ja) | ||
AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
AU2016276806B2 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
JP2006520805A5 (ja) | ||
RU2012117796A (ru) | Производные пиразолиндиона как ингибиторы надфн-оксидазы | |
JP2017527604A (ja) | sGC刺激剤 | |
JP2020514267A5 (ja) | ||
JP2016540017A (ja) | sGC刺激物質 | |
TW201701879A (zh) | Irak4抑制劑組合 | |
JP2007505933A5 (ja) | ||
RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
US10266491B2 (en) | Carbazole derivatives | |
JP2012501312A5 (ja) | ||
TW201200518A (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
JP2009532452A5 (ja) | ||
JP2009529047A5 (ja) | ||
NZ594405A (en) | New adenosine receptor ligands and uses thereof | |
WO2011100607A1 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
JP7337067B2 (ja) | sGC刺激薬 | |
JP2014528479A5 (ja) | ||
JP2008500992A5 (ja) | ||
CA2499134A1 (en) | Fused azole-pyrimidine derivatives | |
JP2009500366A5 (ja) | ||
JP2017527605A (ja) | sGC刺激剤 | |
JP2013508382A5 (ja) |